Postradioiodine Graves' management: The PRAGMA study

Area of Science:

• Endocrinology
• Nuclear Medicine
• Thyroidology

Background:

• Radioiodine (RI) treatment for Graves' disease can lead to unstable thyroid function post-treatment.
• Monitoring and managing thyroid status after RI is crucial for patient outcomes.

Purpose of the Study:

• To quantify the frequency of abnormal thyroid function following RI treatment for Graves' disease.
• To compare the effectiveness of common post-RI management strategies.

Main Methods:

• Retrospective, multicentre observational study of adult patients with Graves' disease treated with RI.
• 12-month follow-up assessing thyroid function (TSH, FT4) and management strategies (antithyroid drugs, levothyroxine, or combination).

Main Results:

• Hypothyroidism occurred in 80.7% and hyperthyroidism in 48.6% of 812 patients post-RI.
• Management strategies (antithyroid drugs, levothyroxine, combination) showed small differences in effectiveness.
• Low adherence to national guidelines for thyroid function monitoring (21.4%-28.7%) in the first 6 months.

Conclusions:

• Dysthyroidism is common in the 12 months following RI treatment for Graves' disease.
• Current management strategies alone are unlikely to resolve the high frequency of dysthyroidism.
• Significant variations in practice and outcomes exist between treatment centers.